Literature DB >> 28253478

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β.

Elizabeth C Mormino1, Kathryn V Papp2, Dorene M Rentz2, Michael C Donohue3, Rebecca Amariglio2, Yakeel T Quiroz4, Jasmeer Chhatwal1, Gad A Marshall2, Nancy Donovan5, Jonathan Jackson1, Jennifer R Gatchel5, Bernard J Hanseeuw1, Aaron P Schultz6, Paul S Aisen3, Keith A Johnson7, Reisa A Sperling8.   

Abstract

INTRODUCTION: Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.
METHODS: We examined amyloid β (Aβ)-related change in several variations of the preclinical Alzheimer cognitive composite (PACC) and each individual PACC component in clinically normal (CN) older participants in the Harvard Aging Brain Study. We then examined the PACC variations in the Alzheimer's Disease Cooperative Study Prevention Instrument Study as a replication cohort.
RESULTS: Aβ+ CN individuals demonstrated longitudinal decline on all individual PACC components and all PACC variations. Aβ group differences emerged earlier when Free and Cued Selective Reminding Test Free Recall was included in the PACC. PACC decline was associated with Clinical Dementia Rating progression. DISCUSSION: This independent data set and a replication cohort confirm the ability of the PACC to capture both early and late cognitive decline during the preclinical stages of Alzheimer's disease, which may prove advantageous in the prevention trial design.
Copyright © 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyloid PET; Cognitive composite; Longitudinal cognitive decline; Preclinical Alzheimer's disease; Secondary prevention

Mesh:

Substances:

Year:  2017        PMID: 28253478      PMCID: PMC5573651          DOI: 10.1016/j.jalz.2017.01.018

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  39 in total

1.  Free and cued selective reminding and selective reminding in the elderly.

Authors:  E Grober; A Merling; T Heimlich; R B Lipton
Journal:  J Clin Exp Neuropsychol       Date:  1997-10       Impact factor: 2.475

2.  Free and cued selective reminding identifies very mild dementia in primary care.

Authors:  Ellen Grober; Amy E Sanders; Charles Hall; Richard B Lipton
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

3.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

Review 4.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort.

Authors:  M F Elias; A Beiser; P A Wolf; R Au; R F White; R B D'Agostino
Journal:  Arch Neurol       Date:  2000-06

6.  Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease.

Authors:  Kathryn V Papp; Elizabeth C Mormino; Rebecca E Amariglio; Catherine Munro; Alex Dagley; Aaron P Schultz; Keith A Johnson; Reisa A Sperling; Dorene M Rentz
Journal:  Neuropsychology       Date:  2015-11-23       Impact factor: 3.295

7.  Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.

Authors:  Ronald C Petersen; Heather J Wiste; Stephen D Weigand; Walter A Rocca; Rosebud O Roberts; Michelle M Mielke; Val J Lowe; David S Knopman; Vernon S Pankratz; Mary M Machulda; Yonas E Geda; Clifford R Jack
Journal:  JAMA Neurol       Date:  2016-01       Impact factor: 18.302

Review 8.  CAP--advancing the evaluation of preclinical Alzheimer disease treatments.

Authors:  Eric M Reiman; Jessica B Langbaum; Pierre N Tariot; Francisco Lopera; Randall J Bateman; John C Morris; Reisa A Sperling; Paul S Aisen; Allen D Roses; Kathleen A Welsh-Bohmer; Maria C Carrillo; Stacie Weninger
Journal:  Nat Rev Neurol       Date:  2015-09-29       Impact factor: 42.937

9.  Screening for predementia AD: time-dependent operating characteristics of episodic memory tests.

Authors:  Carol A Derby; Leah C Burns; Cuiling Wang; Mindy J Katz; Molly E Zimmerman; Gilbert L'italien; Zhenchao Guo; Robert M Berman; Richard B Lipton
Journal:  Neurology       Date:  2013-03-06       Impact factor: 9.910

10.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

View more
  75 in total

1.  Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.

Authors:  Jennifer S Rabin; Aaron P Schultz; Trey Hedden; Anand Viswanathan; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Rachel F Buckley; Hyun-Sik Yang; Michael Properzi; Vaishnavi Rao; Dylan R Kirn; Kathryn V Papp; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal
Journal:  JAMA Neurol       Date:  2018-09-01       Impact factor: 18.302

2.  Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention.

Authors:  Michael S Rafii; Paul S Aisen
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

3.  Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults.

Authors:  Jennifer S Rabin; Rodrigo D Perea; Rachel F Buckley; Taylor E Neal; Randy L Buckner; Keith A Johnson; Reisa A Sperling; Trey Hedden
Journal:  Cereb Cortex       Date:  2019-03-01       Impact factor: 5.357

4.  Temporal changes in the likelihood of dementia and MCI over 18 years in a population sample.

Authors:  Kumar B Rajan; Jennifer Weuve; Robert S Wilson; Lisa L Barnes; Elizabeth A McAninch; Denis A Evans
Journal:  Neurology       Date:  2019-12-05       Impact factor: 9.910

5.  Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.

Authors:  Reisa A Sperling; Michael C Donohue; Rema Raman; Chung-Kai Sun; Roy Yaari; Karen Holdridge; Eric Siemers; Keith A Johnson; Paul S Aisen
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

Review 6.  Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease.

Authors:  Elizabeth C Mormino; Kathryn V Papp
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.

Authors:  Reisa A Sperling; Elizabeth C Mormino; Aaron P Schultz; Rebecca A Betensky; Kathryn V Papp; Rebecca E Amariglio; Bernard J Hanseeuw; Rachel Buckley; Jasmeer Chhatwal; Trey Hedden; Gad A Marshall; Yakeel T Quiroz; Nancy J Donovan; Jonathan Jackson; Jennifer R Gatchel; Jennifer S Rabin; Heidi Jacobs; Hyun-Sik Yang; Michael Properzi; Dylan R Kirn; Dorene M Rentz; Keith A Johnson
Journal:  Ann Neurol       Date:  2019-01-21       Impact factor: 10.422

8.  Timing of onset and rate of decline in learning and retention in the pre-dementia phase of Alzheimer's disease.

Authors:  Ellen Grober; Yang An; Richard B Lipton; Claudia Kawas; Susan M Resnick
Journal:  J Int Neuropsychol Soc       Date:  2019-08       Impact factor: 2.892

9.  Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia.

Authors:  Clifford R Jack; Heather J Wiste; Terry M Therneau; Stephen D Weigand; David S Knopman; Michelle M Mielke; Val J Lowe; Prashanthi Vemuri; Mary M Machulda; Christopher G Schwarz; Jeffrey L Gunter; Matthew L Senjem; Jonathan Graff-Radford; David T Jones; Rosebud O Roberts; Walter A Rocca; Ronald C Petersen
Journal:  JAMA       Date:  2019-06-18       Impact factor: 56.272

10.  Neurogenetic contributions to amyloid beta and tau spreading in the human cortex.

Authors:  Jorge Sepulcre; Michel J Grothe; Federico d'Oleire Uquillas; Laura Ortiz-Terán; Ibai Diez; Hyun-Sik Yang; Heidi I L Jacobs; Bernard J Hanseeuw; Quanzheng Li; Georges El-Fakhri; Reisa A Sperling; Keith A Johnson
Journal:  Nat Med       Date:  2018-10-29       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.